{
  "id": "621ebb733a8413c65300005c",
  "type": "factoid",
  "question": "What is the indication for Favipiravir?",
  "ideal_answer": "Favipiravir (FVP) has been used for treatment of COVID-19 in many countries.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34339547",
    "http://www.ncbi.nlm.nih.gov/pubmed/22809499",
    "http://www.ncbi.nlm.nih.gov/pubmed/34497279",
    "http://www.ncbi.nlm.nih.gov/pubmed/34571361",
    "http://www.ncbi.nlm.nih.gov/pubmed/34044777",
    "http://www.ncbi.nlm.nih.gov/pubmed/33191372",
    "http://www.ncbi.nlm.nih.gov/pubmed/24563658",
    "http://www.ncbi.nlm.nih.gov/pubmed/33364790",
    "http://www.ncbi.nlm.nih.gov/pubmed/32405421",
    "http://www.ncbi.nlm.nih.gov/pubmed/33042544",
    "http://www.ncbi.nlm.nih.gov/pubmed/34592006",
    "http://www.ncbi.nlm.nih.gov/pubmed/24084488",
    "http://www.ncbi.nlm.nih.gov/pubmed/34539392",
    "http://www.ncbi.nlm.nih.gov/pubmed/33647553",
    "http://www.ncbi.nlm.nih.gov/pubmed/34548811",
    "http://www.ncbi.nlm.nih.gov/pubmed/34535038",
    "http://www.ncbi.nlm.nih.gov/pubmed/22429564",
    "http://www.ncbi.nlm.nih.gov/pubmed/33746092",
    "http://www.ncbi.nlm.nih.gov/pubmed/28769016",
    "http://www.ncbi.nlm.nih.gov/pubmed/34464921",
    "http://www.ncbi.nlm.nih.gov/pubmed/28462833",
    "http://www.ncbi.nlm.nih.gov/pubmed/33624584",
    "http://www.ncbi.nlm.nih.gov/pubmed/22022624",
    "http://www.ncbi.nlm.nih.gov/pubmed/29765101",
    "http://www.ncbi.nlm.nih.gov/pubmed/32097670",
    "http://www.ncbi.nlm.nih.gov/pubmed/32645335",
    "http://www.ncbi.nlm.nih.gov/pubmed/33555378",
    "http://www.ncbi.nlm.nih.gov/pubmed/29524445",
    "http://www.ncbi.nlm.nih.gov/pubmed/33130203"
  ],
  "snippets": [
    {
      "text": ". In the COVID-19 era, there has been a race for drugs to be effective against SARS-CoV-2. There are reports about the uses of Remdesivir and Favipiravir as existing antivirals against virus ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34535038",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "key repurposed drugs advocated to treat COVID-19 (lopinavir, ritonavir, ivermectin, remdesivir and favipiravir), ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34497279",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": ": To compare the efficacy and safety of favipiravir and umifenovir (Arbidol) to treat COVID-19 patients",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34539392",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Favipiravir (FPV) and hydroxychloroquine (HCQ) are considered possible COVID-19 treatments",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34548811",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Favipiravir (FVP) has been used for treatment of COVID-19 in many countries. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34592006",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To assess the efficacy of Favipiravir compared to the standard therapy in treating patients with severe COVID-19 infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34464921",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Favipiravir versus standard of care in patients with severe COVID-19 infections",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34464921",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Favipiravir and Molnupiravir, orally available antivirals, have been reported to exert antiviral activity against SARS-CoV-2. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34571361",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Molnupiravir/Favipiravir in the treatment of COVID-19.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34571361",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Favipiravir, indicated for the treatment of new and re-emerging influenza infections, has been suggested to be effective against SARS-CoV-2, although this is not yet fully validated.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33746092",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33647553",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We herein report the first case of a fever induced by favipiravir, a potential coronavirus disease 2019 therapeutic drug.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33191372",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22429564",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: Favipiravir possesses high utility for treating patients with COVID-19.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34044777",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Favipiravir is active against a broad range of influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently emerged A(H7N9) avian virus.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24084488",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Favipiravir is approved in Japan for the treatment of influenza virus infections and has shown promise against other highly pathogenic RNA viruses including CCHFV with demonstrated efficacy in the type I interferon deficient mouse model.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32645335",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Favipiravir, an antiviral drug, is being used for COVID-19 treatment, and we currently have limited information regarding its efficacy and safety.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33364790",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Favipiravir is one such oral drug that was approved for new and reemerging pandemic influenza in Japan in 2014 and has shown potent in vitro activity against severe acute respiratory syndrome coronavirus-2.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33130203",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Favipiravir is an antiviral previously indicated for influenza and Ebola, which has shown some promise in early trials for treatment of COVID-19.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32405421",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "avipiravir, a novel antiviral drug which was mainly used for the treatment of influenza, now has been demonstrated to have a curative effect in treating Ebola virus infection. I",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28462833",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " so far. Favipiravir is a repurposed antiviral agent in treatment of SARS-CoV-2 infection, and to meet the current need, pharmaceutical companies are working for manufacturing licensed generic favi",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33624584",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " demonstrate that Favipiravir [T-705, a drug in advanced clinical development for the treatment of infections with the influenza virus] inhibits in vitro murine norovirus replication. Tim",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22809499",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The combination therapy of Lopinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID-19",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33042544",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "vir, Favipiravir and Ribavirin might be a safer therapeutic option for COVID-19. Recent",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33555378",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34548811",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "AIM: Favipiravir and oseltamivir are antiviral compounds used for the treatment of influenza infec",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24563658",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "WHAT IS KNOWN AND OBJECTIVE: Favipiravir is a promising treatment candidate for managing coronavirus disease 2019 (COVID-19)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34339547",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Favipiravir is expected to be an important therapeutic agent for severe influenza, the next pandemic influenza strain, and other severe RNA virus infections for which standard treatments are not available.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32097670",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Favipiravir, also known as T-705, is an antiviral drug that has been approved in 2014 in Japan to treat pandemic influenza virus infections.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29524445",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Favipiravir (T-705) is a purine analogue antiviral approved for use in Japan against emerging influenza strains; and several phase 2 and 3 clinical trials are ongoing in the United States and Europe.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29765101",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Favipiravir as a potential countermeasure against neglected and emerging RNA viruses.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29524445",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "With its unique mechanism of action and broad range of antiviral activity, favipiravir is a promising drug candidate for influenza and many other RNA viral diseases for which there are no approved therapies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24084488",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Favipiravir has been developed as an anti-influenza drug and licensed as an anti-influenza drug in Japan.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32097670",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Of note is that favipiravir shows anti-viral activities against other RNA viruses such as arenaviruses, bunyaviruses and filoviruses, all of which are known to cause fatal hemorrhagic fever.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28769016",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Favipiravir, an anti-influenza drug against life-threatening RNA virus infections.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32097670",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [],
  "exact_answer": "Covid-19, influenza"
}